William R. Friedenberg, Montserrat Rue, Emily A. Blood, William S. Dalton, Chaim Shustik, Richard A. Larson, Pieter Sonneveld and Philip R. Greipp Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) Cancer 106
Version of Record online: 17 JAN 2006 | DOI: 10.1002/cncr.21666
VAD (vincristine, doxorubicin, and dexamethasone) with and without valspodar (PSC-833) was evaluated in patients with recurring or refractory multiple myeloma. There was no improvement in clinical outcome and there was excess toxicity in the valspodar-treated group compared with VAD alone.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field